Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

novo cover image
$599
Posted in: GLP-1RA, GLP-1RA + Basal, Other Jun 06 | 2022Novo Hosts ADA 2022 Investor EventPurchase Blast
ADA cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jun 04 | 2022ADA 2022 Key Press Releases (June 4)Purchase Blast
ADA cover image
$599
Posted in: Basal Insulin, Glucose Monitoring, Other Jun 03 | 2022ADA 2022 Key Press Releases (June 3)Purchase Blast
abbott cover image
$599
Posted in: Glucose Monitoring May 30 | 2022Abbott's Libre 3 FDA ApprovedPurchase Blast
lilly cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 24 | 2022Mounjaro WAC Pricing Analysis; Lilly @ UBS 2022Purchase Blast
lilly cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 18 | 2022Mounjaro (tirzepatide) Label and Website AnalysisPurchase Blast
lilly cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 13 | 2022Tirzepatide Approved in US as "Mounjaro"Purchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other May 06 | 2022Insulet, Vertex, MannKind, and Intercept Q1 ‘22 Earnings UpdatesPurchase Blast
1 31 32 33 34 35 99

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.